Feds sue to close stem cell clinics in California, FloridaNewsOK.comLOS ANGELES (AP) — Federal prosecutors in California and Florida have sued to stop two companies from providing stem cell treatments, alleging the clinics marketed their procedures as … Continue reading
Feds sue to close stem cell clinics in California, FloridaNewsOK.comLOS ANGELES (AP) — Federal prosecutors in California and Florida have sued to stop two companies from providing stem cell treatments, alleging the clinics marketed their procedures as … Continue reading
New York TimesFDA Moves to Stop Rogue Clinics From Using Unapproved Stem Cell TherapiesNew York TimesDr. Mark Berman, of the Cell Surgical Network, in 2014 at his practice in Beverly Hills. Dr. Berman is a founder of the California Stem Cell Treatment … Continue reading
Feds sue to close stem cell clinics in California, FloridaMinneapolis Star TribuneLOS ANGELES — Federal prosecutors in California and Florida have sued to stop two companies from providing stem cell treatments, alleging the clinics marketed their proce… Continue reading
Los Angeles Times |
US prosecutors sue to shut down clinics selling unproven stem cell treatments in California and Florida
Los Angeles Times The U.S. Department of Justice filed lawsuits Wednesday aimed at shutting down clinics in Florida and California that have marketed unapproved and unproven “stem cell” treatments to thousands of patients, some of whom suffered severe adverse reactions … FDA seeks injunction to stop two stem cell companies after patients blindedWashington Post Feds Sue to Close Stem Cell Clinics in California, FloridaU.S. News & World Report Implanting stem cell ‘patch’ can restore vision – FuturityFuturity: Research News New York Times –FDA.gov all 61 news articles » |
Penn: Office of University Communications |
With second FDA approval, the transformative power of CAR–T is multiplied
Penn: Office of University Communications The technology behind Kymriah originated at Penn from the innovative work led by Penn Medicine’s Carl June in developing the CAR-T platform for reprogramming T cells. An initial cohort of patients was treated with the CAR–T cell therapy at Penn, with … |